Substituted CIS- and trans-stilbenes as therapeutic agents
申请人:Vander Jagt David L.
公开号:US20070249647A1
公开(公告)日:2007-10-25
The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.
SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS
申请人:STC. UNM
公开号:US20130178536A1
公开(公告)日:2013-07-11
The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene. A method of treating or reducing the likelihood of Alzheimer's disease in a patient is an additional embodiment of the present invention.
THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS
申请人:STC. UNM
公开号:US20160287531A1
公开(公告)日:2016-10-06
The present invention relates to method(s) of treating a subject afflicted with a skin disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene or a stilbene hybrid. A method of treating or reducing the likelihood of a skin disease or condition in a patient is an additional embodiment of the present invention. Preferred pharmaceutical compositions of the invention include nanoemulsions comprising a therapeutically effective amount of a substituted cis or trans-stilbene or stilbene hybrid and at least one antibiotic.